Changes in serum lipid concentrations in patients with chronic hepatitis C virus positive hepatitis responsive or non-responsive to interferon therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 2, 2005, Pages 204-208

  Hamamoto, Sachiko ^a   Uchida, Yasushi ^a   Wada, Tomoko ^a   Moritani, Makoto ^a   Sato, Shuichi ^a   Hamamoto, Naoharu ^a   Ishihara, Shunji ^a   Watanabe, Makoto ^a   Kinoshita, Yoshikazu ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Hepatitis C virus; Interferon; Total cholesterol; Triglyceride

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; CHOLESTEROL; CHOLINESTERASE; LIPID; RIBAVIRIN; TRIACYLGLYCEROL; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLINESTERASE BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHOOL CHILD; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 14844283411     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03526.x     Document Type: Article

References (24)

1. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized controlled trial. N. Engl. J. Med. 1989; 321: 1501-6.
2. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murrey L, Waggoner J et al. Recombinant interferon alpha therapy for chronic hepatitis C: a randomized, double- blinded, placebo-controlled trial. N. Engl. J. Med. 1989; 321: 1506-10.
3. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-89.
4. Sakai S, Watanabe M, Fukumoto S. Laparoscopic findings as a predictor of efficacy of interferon therapy and laparoscopic changes in sustained responders after interferon therapy. Dig. Endosc. 1996; 8: 293-301.
5. Lau JY, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501-4.
6. Booth JC, Foster GR, Kumer U, Galassini R, Goldin RD, Brown JL et al. Chronic hepatitis C virus infections: predictive value of genotype and level of viraemia on disease progression and response to interferon alpha. Gut 1995; 36: 427-32.
7. Brouwer JT, Nevens F, Kleter B, Elewaut A, Adler M, Brenard R et al. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients. J. Hepatol. 1998; 28: 951-9.
8. Minuk GY, Weinstein S, Kaita KD. Serum cholesterol and low-density lipoprotein cholesterol levels as predictors of response to interferon therapy for chronic hepatitis. Ann. Intern. Med. 2000; 132: 761-2.
9. Shindo M, Araki K, Okuno T. The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C. J. Hepatol. 1997; 26: 492-7.
10. Tacikowski T, Milewski B, Dzieniszewski J, Nowicka G, Walewska-Zielecka B. Comparative analysis of plasma lipoprotein components assessed by ultracentrifugation in primary biliary cirrhosis and chronic hepatitis. Med. Sci. Monit. 2000; 6: 325-9.
11. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J. Hepatol. 2001; 34: 428-34.
12. Feingold K, Grunfeld C. Role of cytokines in inducing hyperlipidemia. Diabetes 1992; 41: 97-101.
13. Shindo M, Arai K, Sokawa Y, Okuno T. Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon therapy. Ann. Intern. Med. 1995; 122: 586-91.
14. Chemello L, Cavalletto L, Donada C, Bonetti P, Casarin P, Urban F et al. Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. Gastroenterology 1997; 113: 1654-9.
15. Shiratori Y, Kato N, Yokosuka O, Iwazeki F, Hashimoto E, Hayashi N et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 1997; 113: 558-66.
16. Naeem M, Bacon BR, Mistry B, Britton RS, Di Bisceglie AM. Changes in serum lipoprotein profile during interferon therapy in chronic hepatitis C. Am. J. Gastroenterol. 2001; 96: 2468-72.
17. Quadri R, Rubbia-Brandt L, Abid K, Nergo F. Detection of the negative-strand hepatitis C virus RNA in tissues: implications for pathogenesis. Antiviral Res. 2001; 52: 161-71.
18. Fabris C, Federico E, Soardo G, Falleti E, Pirisi M. Blood lipids of patients with chronic hepatitis: differences related to viral etiology. Clin. Chem. Acta. 1997; 261: 159-65.
19. Monazahian M, Bohme J, Bonk S et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J. Med. Virol. 1999; 57: 223-9.
20. Shinohara E, Yamashita S, Kihara S, Hirano K, Ishigami M, Arai T et al. Interferon alpha induces disorder of lipid metabolism by lowering post heparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C. Hepatology 1997; 25: 1502-6.
21. Rosenzweig IB, Wiebe DA, Borden EC, Storer B, Shrago ES. Plasma lipoprotein changes in humans induced by β-interferon. Atherosclerosis 1987; 67: 261-7.
22. Grunfeld C, Dinarello CA, Feingold KR. Tumor necrosis factor-α, interleukin-1, and interferon alpha stimulate triglyceride synthesis in HepG2 cells. Metabolism 1991; 40: 894-8.
23. Yamagishi S, Abe T, Sawada T. Human recombinant interferon α-2a (rIFNα-2a) therapy suppresses hepatic triglyceride lipase, leading to severe hypertriglyceridemia in a diabetic patient. Am. J. Gastoroenterol. 1994; 89: 2280.
24. Fernandez-Miranda C, Pulido F, Carrillo JL, Larumbe S, Gomez Izquierdo T, Ortuno B et al. Lipoprotein alterations in patients with HIV infection: relation with cellular and humoral immune markers. Clin. Chim. Acta. 1998; 274: 63-70.